Abstract
Plasma concentrations of primidone and its metabolite phenobarbitone were monitored in 9 pregnant epileptic patients treated with primidone (and in 3 cases other antiepileptic drugs) given at constant doses throughout pregnancy and the Puerperium. Phenobarbitone plasma concentrations were monitored in another 6 patients given phenobarbitone itself. A trend towards increasing primidone plasma concentrations during the second quarter of pregnancy was evident in all patients, with a concomitant significant decrease in primidone-derived phenobarbitone plasma concentrations. A trend towards a lowering of plasma concentrations of phenobarbitone administered as such was confirmed. These results suggest the usefulness of a careful monitoring of primidone and primidone-derived phenobarbitone during pregnancy and the Puerperium. Discrepancies of findings with primidone and phenobarbitone are discussed in view of the possible mechanism involved.
| Original language | English |
|---|---|
| Pages (from-to) | 252-260 |
| Number of pages | 9 |
| Journal | Clinical Pharmacokinetics |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1984 |
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
- Pharmacology, Toxicology and Pharmaceutics(all)